Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $36.00 at Robert W. Baird

Tandem Diabetes Care (NASDAQ:TNDM) had its price target lifted by Robert W. Baird from $28.00 to $36.00 in a report issued on Friday, Benzinga reports. They currently have a neutral rating on the medical device company’s stock.

Other analysts also recently issued reports about the stock. Leerink Partnrs raised shares of Tandem Diabetes Care from a market perform rating to an outperform rating in a research report on Thursday, April 25th. Citigroup upped their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a neutral rating in a report on Wednesday, April 3rd. SVB Leerink upgraded shares of Tandem Diabetes Care from a market perform rating to an outperform rating and lifted their target price for the company from $34.00 to $45.00 in a report on Thursday, April 25th. StockNews.com upgraded Tandem Diabetes Care from a sell rating to a hold rating in a research note on Friday, April 19th. Finally, Stifel Nicolaus lifted their price objective on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a buy rating in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $43.45.

Tandem Diabetes Care Stock Up 22.3 %

Tandem Diabetes Care stock traded up $8.16 during trading hours on Friday, hitting $44.72. 5,986,916 shares of the stock traded hands, compared to its average volume of 1,279,958. Tandem Diabetes Care has a one year low of $13.82 and a one year high of $47.00. The firm’s 50-day moving average price is $32.29 and its two-hundred day moving average price is $26.08. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. The company has a market cap of $2.89 billion, a PE ratio of -20.61 and a beta of 1.10.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 32.33%. On average, research analysts forecast that Tandem Diabetes Care will post -1.62 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. RiverPark Advisors LLC purchased a new position in Tandem Diabetes Care in the 4th quarter worth about $27,000. MCF Advisors LLC lifted its position in Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares during the period. Signaturefd LLC boosted its holdings in Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after purchasing an additional 1,517 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in Tandem Diabetes Care by 141.6% in the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock worth $66,000 after purchasing an additional 1,085 shares during the period. Finally, GAMMA Investing LLC purchased a new stake in Tandem Diabetes Care during the 4th quarter valued at $73,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.